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Background: Pressure unloading induces the regression of left ventricular myocardial
hypertrophy (LVH). Recent findings indicate that pharmacological activation of the
soluble guanylate cyclase (sGC) – cyclic guanosine monophosphate (cGMP) pathway
may also exert reverse-remodeling properties in the myocardium. Therefore, we aimed
to investigate the effects of the sGC activator cinaciguat in a rat model of LVH and
compare it to the “gold standard” pressure unloading therapy.
Methods: Abdominal aortic banding was performed for 6 or 12 weeks. Sham
operated animals served as controls. Pressure unloading was induced by removing
the aortic constriction after week 6. The animals were treated from week 7 to 12,
with 10 mg/kg/day cinaciguat or with placebo p.o., respectively. Cardiac function
and morphology were assessed by left ventricular pressure-volume analysis and
echocardiography. Additionally, key markers of myocardial hypertrophy, fibrosis, nitro-
oxidative stress, apoptosis and cGMP signaling were analyzed.
Results: Pressure unloading effectively reversed LVH, decreased collagen accumulation
and provided protection against oxidative stress and apoptosis. Regression of LVH
was also associated with a full recovery of cardiac function. In contrast, chronic
activation of the sGC enzyme by cinaciguat at sustained pressure overload only slightly
influenced pre-established hypertrophy. However, it led to increased PKG activity and
had a significant impact on interstitial fibrosis, nitro-oxidative stress and apoptosis.
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Amelioration of the pathological structural alterations prevented the deterioration of LV
systolic function (contractility and ejection fraction) and improved myocardial stiffness.
Conclusion: Our results indicate that both cinaciguat treatment and pressure unloading
evoked anti-remodeling effects and improved LV function, however in a differing
manners.
Keywords: left ventricular hypertrophy, pressure unloading, reverse remodeling, cinaciguat, cGMP
INTRODUCTION
Chronic pressure overload (PO) of the left ventricle induces the
manifestation of pathological left ventricular (LV) myocardial
hypertrophy (LVH). The hypertrophic remodeling of the
myocardium incorporates increased cardiomyocyte growth,
reactive interstitial fibrosis (Creemers and Pinto, 2011), enhanced
nitro-oxidative stress and apoptosis (Teiger et al., 1996; Takimoto
and Kass, 2007). In the long term, these pathological cellular
processes collectively lead to progressive deterioration of cardiac
function.
Preclinical, as well as clinical, evidence suggests, that
termination of the pathological stimulus of PO by a pressure
unloading therapy (antihypertensive therapy, aortic valve
replacement) leads to the regression of LVH, a phenomenon
called myocardial reverse remodeling (Gao et al., 2005; Ruppert
et al., 2016; Treibel et al., 2018). This process involves reduction
in LV mass, decreased interstitial collagen accumulation, and
improvement in both systolic and diastolic function (Ikonomidis
et al., 2001; Biederman et al., 2011).
Besides pressure unloading, an additional therapeutic option
in case of PO-induced LVH might be the direct pharmacological
modulation of cardiomyocyte signaling (enhancing protective
pathways or/and silencing pro-hypertrophic signal transduction)
without influencing the elevated PO. In recent years, the
protective role of the guanylate cyclase (GC) – cyclic guanosine
monophosphate (cGMP) – protein kinase G (PKG) pathway
in the cardiovascular system, and its therapeutic potential
has been intensely investigated (Kraehling and Sessa, 2017).
Briefly, under physiological conditions this axis consists of the
following signaling cascade. The gaseous transmitter nitric oxide
(NO) binds to and subsequently activates the sGC enzyme,
which in turn generates the second messenger cGMP. The
elevated cytoplasmic cGMP content potentiates the activity of
the PKG enzyme which finally regulates many cellular processes
by phosphorylating its target proteins (Moncada et al., 1991).
However, in various cardiovascular pathologies including LVH
the intensified formation of reactive oxygen species (ROS)
interferes with the above mentioned signaling via several
mechanisms. These include (1) decreased NO production due to
the oxidation of the endothelial NO synthase, (2) reduced NO
bioavailability (3) and oxidation of the sGC enzyme rendering it
a hem-free and NO-insensitive form (Stasch et al., 2011).
To restore the dysfunctional sGC-cGMP-PKG pathway,
numerous pharmacological interventions have been
proposed, such as inhibitors of the cGMP-degrading enzyme
phosphodiesterase (PDE)-5, sGC stimulators and activators
(Kraehling and Sessa, 2017). Due to their special mode of action,
sGC activators represent one of the most promising agents
in this drug family. This class of compounds preferentially
activates the oxidized, hem-free and NO-insensitive form of the
sGC enzyme, ensuring adequate cGMP production even under
pathological conditions characterized by oxidative stress (Stasch
et al., 2011). Indeed, during preclinical drug-development sGC
activators have been successfully tested in animal models of
ischemia-reperfusion injury (Korkmaz et al., 2009), diabetic
cardiomyopathy (Matyas et al., 2015), and congestive heart
failure (Fraccarollo et al., 2014). Furthermore, in PO-induced
LVH models, their potent anti-fibrotic and anti-hypertrophic
action proved to be, at least in part, independent of blood
pressure reduction, raising the possibility to use them as an
alternative to pressure unloading therapy (Masuyama et al., 2009;
Costell et al., 2012; Nemeth et al., 2016).
Cinaciguat (BAY 58-2667) is the initially developed and
most potent sGC activator to date (Stasch et al., 2011). Due
to its favorable pharmacodynamic properties, cinaciguat was
quickly launched to the clinical phases of drug development.
After displaying convincing safety and tolerability profile (Frey
et al., 2008), it successfully accomplished the proof-of-concept
study with the indication of acute decompensated heart failure
(Lapp et al., 2009). However, during the phase IIb trial,
its intravenous administration evoked serious hypotension
episodes, which resulted in premature termination of the study
(Gheorghiade et al., 2012). Therefore, the investigators concluded
that cinaciguat should be applied in clinical settings when not
the acute hemodynamic effects, but rather the chronic anti-
remodeling properties are prevailed.
In the present study we aimed to investigate the reverse-
remodeling effects of long term cinaciguat administration in a rat
model of LVH and compare it to the “gold standard” pressure
unloading therapy.
MATERIALS AND METHODS
Animals
The investigation conformed to the EU Directive 2010/63/EU
and the Guide for the Care and Use of Laboratory Animals
used by the US National Institutes of Health (NIH Publication
No.85–23, revised 1996). This investigation was approved by the
ethics committee of the Land Baden-Württemberg for Animal
Experimentation (G-94/15). Sprague-Dawley rats (n = 72) (160–
180 g; Janvier, France) were kept under standard conditions
(22± 2◦C with 12 h light/dark cycles) and were allowed access to
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laboratory rat diet and water ad libitum. To prevent the possible
influential effect of gender on the development and regression of
PO-induced LVH, only male rats were used in this study.
Abdominal Aortic Banding and
Debanding
After a 1-week-long acclimatization period, the rats underwent
abdominal aortic banding (AB; n = 39) or a sham operation
(n = 33), according to the previously described protocol
(Ruppert et al., 2017). In brief, anesthesia was induced by
5% of isoflurane gas in a chamber and maintained by
inhalation from a connected tube with 1.5–2% of isoflurane
in O2. The animals were placed in a supine position on
a heating pad to maintain the core temperature at 37◦C,
measured via a rectal probe. The surgery was performed in
midline laparotomy under sterile conditions. After dissecting
the peritoneum, the abdominal aorta was isolated from the
surrounding connective tissue and subsequently constricted to
the external diameter of a 22-gauge needle above the right
renal artery and below the superior mesenteric artery. The
abdominal muscle layer was sutured in a single, interrupted
fashion. Finally, the skin was closed using surgical clips. Sham
operations consisted of the same procedure except the aortic
constriction. At week 6, to induce pressure unloading in a
group of AB animals (n = 9), the narrowing suture and
the surrounding reactive fibrotic tissue was removed from
the aorta (debanded). Postoperative analgesia was ensured by
subcutaneously administered buprenorphine in the dose of
0.05 mg/kg.
Experimental Groups and Design,
Chronic Treatment Protocol
Six weeks after AB or sham operation the animals were
randomized into 7 experimental groups (Figure 1). One-one
group of the AB (n = 10) and sham operated (n = 11)
animals were terminated after week 6 to prove that PO-
induced myocardial alterations were already present at this
time point. The other five groups were followed up until
week 12, and they were treated from the 7th to the 12th
experimental week with 0.5% methylcellulose vehicle or with
the sGC activator, cinaciguat in suspension. Accordingly, these
groups involved the followings: vehicle treated control group
(Sham-Co, n = 11), cinaciguat treated control group (Sham-
Cin, n = 11), vehicle treated AB group (AB-Co, n = 11),
cinaciguat treated AB group (AB-Cin, n = 9) and vehicle
treated debanded group (Debanded, n = 9). These five groups
were arranged into two experimental set-ups. Comparison of
four groups (Sham-Co, AB-Co, AB-Cin, and Debanded) was
carried out to detect the reverse-remodeling effects of pressure
unloading and cinaciguat. In a separate study, the potential
side effects of chronic cinaciguat treatment was also assessed
in healthy rats (Sham-Co vs. Sham-Cin; see Supplementary
File).
Cinaciguat was administered in the dose of 10 mg/kg/day via
an oral gavage. The body weight of the rats was measured every
day during the whole experimental protocol, and the exact dosage
of Cinaciguat was adjusted accordingly.
Echocardiography
To detect the temporal development of LVH and its regression
by pressure unloading therapy or cinaciguat treatment, serial
echocardiography was performed after week 6 and 12 (Ruppert
et al., 2016). In brief, anesthesia was provided by isoflurane
inhalation. Transthoracic echocardiography was performed by
using an HDI 5000 CV echocardiography machine (ATL
Ultrasound, Philips, Bothell, WA, United States) equipped with
a 10-MHz linear probe. Two-dimensional parasternal long-
axis and short-axis images as well M-mode recordings at
the mid-papillary muscle level were assessed. The study was
completed by analyzing the digital images in a blinded fashion
using an image analyzing software (HDI Lab, Philips, Bothell,
WA, United States). From the recorded images the following
parameters were measured: LV anterior wall thickness (AWT),
LV posterior wall thickness (PWT) and LV internal diameter
(LVID) in diastole (index: d) and systole (index: s). End-diastolic
and end-systolic time points were defined, as the largest and
the smallest LV dimensions. All values were calculated as the
average from three consecutive cardiac cycles. LV mass was
calculated to estimate the myocardial weight using the Devereux
formula: LV mass (g) = {[(LVEDD + AWTd + PWTd)3 –
LVEDD3] × 1.04} × 0.8 + 0.14 (Devereux et al., 1986).
LV mass index was also calculated by normalizing the
LV mass value to the body weight. Cardiac function was
assessed by fractional shortening (FS), calculated as [(LVEDD-
LVESD)/LVEDD]× 100.
P–V Analysis
Pressure–volume (P–V) analysis was performed as previously
described (Olah et al., 2016). At the end of the experimental
period (after week 6 or 12, respectively) the rats were anesthetized
with sodium pentobarbital (60 mg/kg ip.), tracheotomized
and intubated to facilitate breathing. A polyethylene catheter
was inserted into the left external jugular vein for fluid
administration. A 2F microtip pressure-conductance catheter
(SPR-838, Millar Instruments, Houston, TX, United States) was
inserted into the right carotid artery and subsequently advanced
into the ascending aorta. Following 5 min stabilization period,
arterial blood pressure was recorded. Then the catheter was
guided to the LV under pressure control. With the use of
a special P–V analysis program (PVAN, Millar Instruments,
Houston, TX, United States) systolic blood pressure (SBP),
diastolic blood pressure (DBP), mean arterial pressure (MAP),
LV end-systolic pressure (LVESP), LV end-diastolic pressure
(LVEDP), ejection fraction (EF), arterial elastance (Ea), and time
constant of LV pressure decay [TauG; according to the Glanz
method (Yamamoto, 2010)] were computed and calculated.
In order to detect load-independent sensitive contractility
parameters, the P–V loops were also registered at transiently
decreasing preload, which was achieved by the occlusion of
the inferior caval vein. The slope of the end systolic pressure–
volume relationship (ESPVR, according to the linear model)
was calculated as a reliable LV contractility index. The slope of
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FIGURE 1 | Experimental design. After a 1-week-long acclimatization period (at week 0), the rats underwent abdominal aortic banding (AB; n = 39) or a sham
operation (n = 33). Six weeks later, the animals were randomized into seven experimental groups. A group of AB (n = 10) and sham-operated (n = 11) animals were
measured after week 6 to prove that pressure overload-induced myocardial alterations were already present at this time point. The other five groups were followed
up until week 12 and they were treated from the 7th to the 12th experimental week with 0.5% methylcellulose vehicle or with the sGC activator, cinaciguat in
suspension (10 mg/kg/day via an oral gavage). Accordingly, these groups involved the followings: vehicle-treated control group (Sham-Co, n = 11), cinaciguat-treated
control group (Sham-Cin, n = 11), vehicle-treated AB group (AB-Co, n = 11), cinaciguat-treated AB group (AB-Cin, n = 9) and vehicle-treated debanded group
(Debanded, n = 9). Comparison of Sham-Co, AB-Co, AB-Cin, and Debanded groups were performed to detect the potential reverse remodeling effects of pressure
unloading and chronic cinaciguat treatment. Furthremore, the Sham-Cin group was compared to the Sham-Co group to explore any side effects of cinaciguat.
the LV end-diastolic pressure-volume relationship (EDPVR) was
defined as a precise index of LV stiffness.
Parallel conductance was calculated and volume calibration of
the conductance system was performed as previously described
(Pacher et al., 2008).
After completion of the hemodynamic measurements, blood
samples were collected and the animals were euthanized by
exsanguination. After that, the tibial length (TL) and the heart
weight (HW) were measured to assess HW/TL ratio.
Histology
After euthanasia, the hearts were immediately harvested, fixed
in buffered paraformaldehyde solution (4%) and embedded
in paraffin. Transverse, transmural, 5-µm thick slices of the
ventricles were sectioned and placed on adhesive slides.
Hematoxylin and eosin staining was performed to measure
cardiomyocyte diameter (CD) (Olah et al., 2016). In each sample,
100 longitudinally oriented cardiomyocytes from the LV were
examined, and the diameters at transnuclear position were
defined. The mean value of 100 measurements represented one
sample.
Assessment of cardiac fibrosis was carried out on Masson’s
trichrome stained sections (Ruppert et al., 2016). The myocardial
collagen content was determined by semi quantitative
morphometry scoring of the sections according to the followings:
0: absent, 1: slight, 2: moderate, 3: intense. Twenty randomly
selected visual fields of the LV were assessed and the mean value
represents one sample.
Nitrotyrosine immunohistochemistry was performed to
evaluate nitro-oxidative stress in the myocardium, as previously
described (Matyas et al., 2015). In brief, paraffin embedded
samples were deparaffinized. Following antigen retrieval (0.1
mmol/L citrate buffer, pH 3, heating in microwave oven for
15 min), sections were immunostained with polyclonal rabbit
anti-nitrotyrosine antibody (1:200; overnight, 4◦C, Millipore,
Billerica, MA, United States). To visualize the labeling, HRP-
conjugated avidin (Vectastain ABC kit, Vector Laboratories,
Burlingame, CA, United States, 30 min, room temperature) and
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black colored nickel-cobalt enhanced diaminobenzidine (Vector
Laboratories, 6 min, room temperature) were utilized. Staining
intensity was determined using ImageJ (NIH, Bethesda, MD,
United States).
Terminal deoxynucleotidyl transferase dUTP nick end
labeling (TUNEL) was used to detect DNA strand breaks in LV
myocardium (Matyas et al., 2015). TUNEL assay was carried
out using a commercial available kit (DeadEndTM Colorimetric
TUNEL System, Promega, Mannheim, Germany) according to
the manufacturer’s protocol. Sections were rehydrated, treated
with 20 µg/ml Proteinase K to retrieve antigenic epitopes for
antibody labeling (at RT, 15 min). After washing, sections were
refixed in 4% paraformaldehyde and treated with a mixture of
98 µl Equilibration Buffer, 1 µl Biotinylated Nucleotide Mix and
1µl recombinant Terminal Deoxynucleotidyl Transferase (rTdT)
enzyme (at 37◦C, 60 min) to incorporate biotinylated nucleotides
at the 3′-OH DNA ends. After washing, 0.3% hydrogen peroxide
(H2O2) was used to quench endogenous peroxidase activity.
HRP-labeled streptavidin and 3,3′-diaminobenzidine was used
to detect incorporated nucleotides. The ratio of TUNEL positive
nuclei /total nuclei was calculated on 5 LV sections from each
sample using ImageJ (NIH, Bethesda, MD, United States).
Histological evaluations were conducted by an investigator
blinded to the experimental design.
Cardiac mRNA Analysis
mRNA expression levels in LV samples were analyzed by qRT-
PCR, as previously described (Korkmaz-Icoz et al., 2016). Briefly,
∼25 mg of frozen myocardial tissue samples from the LV were
homogenized in a lysis buffer (RLT buffer; Qiagen, Hilden,
Germany) using the Tissue Lyzer LT (Qiagen) system. RNA was
isolated using the RNeasy Fibrous Tissue Mini Kit (Qiagen)
according to the manufacturer’s instructions. The quality and the
concentration of the isolated RNA was obtained photometrically
by measuring the optical density at 230, 260, and 280 nm.
Reverse transcription reaction (1 µg total RNA in a reaction
volume of 20 µl) was completed using the QuantiTect Reverse
Transcription Kit (Qiagen). Quantitative real-time PCR was
performed with the LightCycler 480 system using LightCycler
480 Probes Master and Universal ProbeLibrary Probes (Roche,
Mannheim, Germany). Primers were obtained from TIB Molbiol
(Berlin, Germany) for the following genes: atrial natriuretic
peptide (ANP), α myosin heavy chain (MHC) and β-MHC
(ratio of β/α-MHC expression was assessed as pathological
cardiomyocyte hypertrophy marker), collagen type 1 α 1
(Col1a1), collagen type 3 α 1 (Col3a1), matrix metalloproteinase
(MMP)-2, and its endogenous inhibitor, tissue inhibitor of MMP
(TIMP)-2, transforming growth factor beta (TGF-β), NOX2:
NADPH oxidase family member 2, also known as gp91phox,
glutathione peroxidase 4 (GPX4) and protein kinase G1 (PKG1).
Gene expression data were normalized to glyceraldehyde-3-
phosphate dehydrogenase (GAPDH). All results are expressed as
values normalized to a positive calibrator (a pool of cDNA from
all samples of the corresponding sham group). The evaluation
was performed with LightCycler 480 SW 1.5 software (Roche,
Mannheim, Germany). For sequences of the utilized primers, see
the Supplementary Table S1.
Western Blot
Western blot measurement from LV samples was performed
as previously described (Ruppert et al., 2017). In brief, LV
myocardial tissue samples were lysed mechanically by the
Tissue Lyzer LT system (Qiagen) and chemically by RIPA buffer
(Melford, Ipswich, United Kingdom), in order to release the
proteins of interest. The concentrations of the extracted proteins
were measured by Bradford assay. Then, a total of 20 µg/30 µl
protein homogenates were denaturated at 70◦C, separated on
sodium dodecyl sulfate polyacrylamide electrophoresis gels and
transferred to polyvinylidene fluoride membranes (Millipore,
Darmstadt, Germany) under semi-dry conditions. After the
transfer, the membranes were washed and blocked for 1 h in 5%
of BSA in Tris-Buffered Saline Tween 20 at room temperature
in order to reduce the non-specific binding of antibodies.
Then, the membranes were incubated overnight at 4◦C with
the following primary antibodies: anti-PKG antibody (1:2000,
ADI-KAP-PK005F, Enzo Life Sciences), anti-vasodilator-
stimulated phosphoprotein (VASP) antibody (1:1000, 3112 Cell
Signaling, Danvers, MA, United States), anti-phospho-VASP
(Ser239) antibody (1:1000, 3114, Cell Signaling, Danvers, MA,
United States), anti-B cell lymphoma 2 (Bcl-2) antibody (1:1000
Cell Signaling, Danvers, MA, United States). The blots were
washed to remove excessive primary antibody binding and
incubated with horseradish peroxydase conjugated secondary
antibody (1:5000 dilution, Santa Cruz Biotechnology, Heidelberg,
Germany) for 1 h at room temperature. Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) housekeeping protein was
used for protein normalization. The immunoreactive protein
bands were developed using the Enhanced Chemiluminescence
system (PerkinElmer, Rodgau-Juegesheim, Germany). The
intensity of the immunoblot bands was detected with Chemi-
smartTM 5100 (Peqlab, Biotechnologie, GmbH, Erlangen,
Germany).
Cyclic Nucleotide Assays
Level of plasma cGMP was measured by enzyme immunoassay
(EIA) using a commercially available kit (Amersham cGMP
EIA Biotrak System, GE Healthcare, Buckinghamshire,
United Kingdom). Myocardial cGMP level was also determined
by EIA (Direkt cGMP ELISA kit, Enzo Life Sciences,
Farmingdale, NY, United States) after homogenization in
0.1 M HCL solution.
Drugs
Cinaciguat (BAY 58-2667; 4-({(4-carboxybutyl)[2-(2-{[4-(2-
phenylethyl)benzyl]oxy}phenyl)ethyl]amino}methyl)benzoic
acid) was kindly provided by Bayer HealthCare (Wuppertal,
Germany). Cinaciguat was suspended in 0.5% methylcellulose
solution, which was purchased from Sigma-Aldrich (St. Louis,
MO, United States).
Sample Sizes
All of the rats underwent echocardiography, P–V analysis (except
one rat from the AB group at week 6, in which the catheter could
not be guided to the LV) and post mortem organ measurement
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(to detect HW/TL ratio). For histology and molecular biology, LV
myocardial tissue was collected from the same animals that were
used for in vivo measurements. Evaluation of CD and fibrosis
score was performed on each samples from all of the experimental
groups. TUNEL staining was carried out in 9–10 samples per
group. 3- NT staining, PCR and WB were conducted on 5–6
samples per group. Plasma and myocardial cGMP levels were
assessed in 4–5 samples per group.
Statistics
All values are expressed as mean ± standard error of the
mean (SEM). The normal distribution of the datasets was
analyzed by D’Agostino Pearson omnibus normality test and
Kolmogorov–Smirnov test. To compare two groups (AB vs.
Sham at week 6 to confirm the presence of LVH; Sham-Co vs.
Sham-Cin to show if cinaciguat treatment has any effects in non-
diseased animals) unpaired Student t-test or Mann–Whitney
test was performed. To detect differences among 4 groups
(Sham, AB-Co, AB-Cin, Debanded) one-way analysis of variance
(ANOVA) followed by Tukey’s post hoc test, or Kruskal–Wallis
test followed by Dunn’s post hoc test was utilized, depending
on the distribution of the datasets. Paired Student’s t-test or
Wilcoxon signed-rank test was performed for comparing data of
the echocardiographic measurements at 2 time points within a
group. Differences were considered statistically significant when
p< 0.05.
RESULTS
Effect of Cinaciguat and Pressure
Unloading on LVH
Pathological LVH was present after 6 weeks of AB, as evidenced
by an increased HW, HW/BW, HW/TL, LV mass, LV mass
index, LVAWs, LVAWd, LVPWd, CD and β/α-MHC ratio
compared to the corresponding sham group (Figure 2A, Table 1,
and Supplementary Table S2). At week 12, in the AB-Co
group, the hypertrophy markers (HW, HW/BW, HW/TL, LV
mass, LV mass index, LVAWd, LVPWd, CD and β/α-MHC
ratio) were also significantly increased when compared to
the corresponding sham group (Figure 2B, Table 1, and
Supplementary Table S3).
LVH was only slightly affected by chronic cinaciguat
treatment, and HW, HW/BW, HW/TL, LV mass, LV mass index,
LVAWd, LVPWs and LVPWd remained increased compared to
the sham group. However, the CD and β/α-MHC ratio were
decreased in the AB-Cin group compared to the AB-Co group
(Figure 2B, Table 1, and Supplementary Table S3).
In contrast, pressure unloading resulted in the regression of
LVH as reflected by the decreased HW/TL, LV mass, LV mass
index, LVAWs, LVAWd, CD and β/α-MHC ratio in the debanded
group when compared to the AB-Co group (Figure 2B and
Table 1).
No differences could be detected in any hypertrophy markers
between the Sham-Co and the Sham-Cin groups (Supplementary
Figure S1 and Supplementary Tables S4, S5).
Myocardial Fibrosis Is Attenuated Either
by Cinaciguat or Pressure Unloading
At week 6, activation of pro-fibrotic genes on the mRNA level
(TGF-β, MMP-2, TIMP-2, Col1a1, Col3a1) was detected in
the AB group (Figure 3A). However, at this time point, no
histopathological evidence of intensified collagen accumulation
could be observed (Figure 3A). In contrast, at week 12,
myocardial fibrosis was significantly increased in the AB-Co
group (Figure 3B). mRNA levels of pro-fibrotic genes still
showed a strong tendency toward increased values in the AB-
Co group when compared to the corresponding Sham group,
however, a significant difference was only observed in the
expression of MMP-2 (Figure 3B). Cinaciguat evoked a potent
anti-fibrotic effect and completely inhibited the PO- induced
collagen accumulation in the myocardium. Accordingly, the
fibrosis score detected by Masson’s trichrome staining was
significantly decreased in the AB-Cin group compared to
the AB-Co group (Figure 3B). In addition, increased MMP-
2 expression was also normalized by cinaciguat (Figure 3B).
Similar to cinaciguat treatment, pressure unloading also provided
protection against fibrotic alterations of the myocardium
(Figure 3B). Cinaciguat treatment exerted no effect on
myocardial fibrosis in sham rats (Supplementary Figure S1).
Oxidative Stress Is Inhibited Both by
Cinaciguat Treatment and Pressure
Unloading
In the AB group, at week 6, increased 3-nitrotyrosine (3-NT)
content of cardiomyocytes and increased mRNA levels of NOX2
and GPX4 indicated increased oxidative stress (Figure 4A). These
parameters showed similar alterations in the AB-Co group at
week 12, although the increment in GPX4 did not reach the level
of significance. Both cinaciguat treatment and pressure unloading
effectively reduced 3-NT content in the myocardium, decreased
the expression of NOX2, and increased the expression of GPX4,
thereby providing protection against oxidative stress (Figure 4B).
Chronic administration of cinaciguat did not influence oxidative
stress in LV myocardium in sham operated rats (Supplementary
Figure S2).
Both Cinaciguat Treatment and Pressure
Unloading Provoked Anti-apoptotic
Effects
At week 6, none of the apoptotic markers (TUNEL staining or
Bcl-2 protein expression) showed alterations in the AB group
(Figure 5A). However, at week 12, the number of TUNEL
positive nuclei increased in the AB-Co group. Furthermore,
significantly decreased protein expression of Bcl-2 was observed
in the AB-Co group compared to its corresponding sham
group. These alterations were successfully prevented either
by cinaciguat treatment or pressure unloading (Figure 5B).
Regarding apoptosis, no differences could be observed between
the Sham-Co and the Sham-Cin groups (Supplementary
Figure S2).
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FIGURE 2 | Effect of pressure unloading and soluble guanylate cyclase activation on pre-established left ventricular hypertrophy. Representative cross-sectional
whole heart images, M-mode echocardiographic recordings at the mid-papillary level and hematoxylin-eosin stained sections (Magnification, ×400; scale bar,
50 µm) are shown in the study groups. (A) Aortic banding (AB) induced the development of left ventricular (LV) myocardial hypertrophy (LVH) already at week 6, as
detected by increased heart weight-to-tibial length ratio (HW/TL), LV mass, cardiomyocyte diameter (CD) and beta/alpha myosin heavy chain ratio (β/α-MHC).
(B) Pressure unloading was associated with the regression of LVH, as observed in decreased HW/TL, LV mass, CD and β/α-MHC. In contrast, treatment with
cinaciguat only slightly influenced the pre-established LVH and only CD and β/α-MHC showed decrement from the non-treated AB group. ∗P < 0.05 vs.
age-matched sham. #P < 0.05 vs. AB-Co. $P < 0.05 vs. AB-Cin.
Effect of Cinaciguat Treatment and
Pressure Unloading on Left Ventricular
Function
At week 6, AB was associated with increased SBP, DBP, MAP,
Ea, maintained EF and FS, increased cardiac contractility
(ESPVR), impaired active relaxation (TauG) and myocardial
stiffness (EDPVR) (Figure 6A, Table 1, and Supplementary
Table S2). At week 12, evident sings of increased afterload (SBP,
DBP, MAP and Ea) and diastolic dysfunction (TauG, EDPVR)
were present in the AB-Co group, similar to the 6-week state
(Figure 6B and Supplementary Table S3). However, at this
time point, a reduction of maladaptive contractility augmentation
(decreased ESPVR) and an impairment of EF and FS values
confirmed deteriorated systolic function as well (Figure 6B and
Table 1). Cinaciguat treatment did not influence PO (Figure 6B
and Supplementary Table S3). In contrast, it inhibited the
decrement in cardiac contractility (ESPVR), and maintained
adequate EF and FS (Figure 6B and Table 1). Concerning
the diastolic dysfunction, myocardial stiffness was improved
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and the values of EDPVR did not differ from the control
group (Figure 6B). However, prolonged active relaxation (TauG)
remained unchanged (Figure 6B).
Removal of the aortic constriction resulted in reduced MAP
and Ea values, confirming a successful pressure unloading
procedure (Figure 6B). Decreased PO led to the restoration of
all the hypertrophy-associated systolic and diastolic functional
alterations in the debanded group (Figure 6B and Table 1).
In healthy, sham-operated rats, chronic administration of
cinaciguat did not decrease arterial blood pressure (SBP, DBP,
MAP) and Ea (Supplementary Figure S3 and Supplementary
Table S5). Furthermore, we detected no differences in systolic
and diastolic function in the Sham-Cin group compared to the
Sham-Co group (Supplementary Figure S3 and Supplementary
Table S4).
Effect of Cinaciguat Treatment and
Pressure Unloading on cGMP Signaling
At week 6, in the AB group an increased ANP mRNA level,
along with increased plasma and myocardial cGMP contents,
were detected. At this time point, the expression level of PKG
differed neither on the mRNA, nor on the protein level. PKG
activity was also unchanged as reflected by the p-VASP/VASP
ratio (Figure 7A).
At week 12, ANP expression, plasma and myocardial cGMP
levels were also elevated in the AB-Co group compared to its
corresponding sham group. Furthermore, mRNA and protein
levels of PKG showed an increasing tendency. Despite the
increased myocardial cGMP level and the increased enzyme pool,
no alteration in PKG activity was observed (Figure 7B).
In the cinaciguat treated group, the enhanced ANP mRNA
and plasma cGMP levels were decreased, however myocardial
cGMP levels remained high. The same tendencies in PKG
mRNA and protein expressions were also present. In addition,
p-VASP/VASP ratio was increased confirming an enhanced PKG
activity (Figure 7B).
Pressure unloading normalized the increased ANP and
plasma/myocardial cGMP levels. No alterations could be detected
in PKG expression or activity (Figure 7B).
In sham operated rats, chronic cinaciguat treatment had no
effect on ANP and PKG expression, PKG activity or plasma
cGMP level. However, an increased myocardial cGMP content
was observed in the Sham-Cin group compared to the Sham-Co
group (Supplementary Figure S4).
DISCUSSION
In the present study we aimed to compare the reverse-remodeling
properties of the sGC activator, cinaciguat, with pressure
unloading therapy in a rat model of AB-induced LVH. We
found, that both interventions exerted potent reverse-remodeling
effects, however, via different mechanisms. Pressure unloading
resulted in the termination of PO, and thereby led to the
regression of the pre-established LVH. In contrast, long term
administration of cinaciguat at sustained PO had only a slight
TABLE 1 | Effects of pressure unloading and cinaciguat therapy on echocardiographic parameters during the development of LVH.
Sham (n = 11) AB-Co (n = 11) AB-Cin (n = 9) Debanded (n = 9)
6th week
Body weight (g) 466 ± 6 446 ± 12 486 ± 9 486 ± 17
HR (beats/min) 336 ± 9 361 ± 14 371 ± 12 362 ± 14
LVAWs (mm) 3.60 ± 0.14 4.22 ± 0.14∗ 4.42 ± 0.20∗ 4.12 ± 0.06∗
LVAWd (mm) 1.94 ± 0.05 2.67 ± 0.06∗ 2.59 ± 0.07∗ 2.68 ± 0.07∗
LVIDs (mm) 5.05 ± 0.07 5.19 ± 0.21 5.16 ± 0.29 5.11 ± 0.18
LVIDd (mm) 8.27 ± 0.12 8.39 ± 0.12 8.50 ± 0.15 8.39 ± 0.15
LVPWs (mm) 3.29 ± 0.10 3.86 ± 0.09 4.02 ± 0.21∗ 4.01 ± 0.04∗
LVPWd (mm) 1.95 ± 0.11 2.59 ± 0.07∗ 2.67 ± 0.15∗ 2.71 ± 0.05∗
LV mass index (g/cm) 2.75 ± 0.06 4.58 ± 0.16∗ 4.27 ± 0.18∗ 4.38 ± 0.21∗
FS (%) 39 ± 1 38 ± 2 39 ± 3 39 ± 1
12th week
Body weight (g) 568 ± 9† 554 ± 14† 575 ± 13† 561 ± 14†
HR (beats/min) 331 ± 12 366 ± 11 358 ± 16 368 ± 14
LVAWs (mm) 3.57 ± 0.14 3.92 ± 0.10† 4.17 ± 0.17 3.53 ± 0.11$†
LVAWd (mm) 1.99 ± 0.08 2.77 ± 0.06∗ 2.52 ± 0.08∗ 2.13 ± 0.07#$†
LVIDs (mm) 5.15 ± 0.13 6.62 ± 0.30∗† 5.89 ± 0.36† 5.32 ± 0.20#
LVIDd (mm) 8.42 ± 0.08† 8.90 ± 0.22† 9.10 ± 0.30† 8.58 ± 0.17
LVPWs (mm) 3.19 ± 0.14 3.59 ± 0.09† 3.84 ± 0.20∗† 3.53 ± 0.17†
LVPWd (mm) 1.98 ± 0.09 2.59 ± 0.05∗ 2.33 ± 0.08∗† 2.27 ± 0.11†
LV mass index (g/cm) 2.45 ± 0.08† 4.17 ± 0.24∗† 3.58 ± 0.23∗† 2.90 ± 0.13#†
FS (%) 39 ± 1 26 ± 2∗† 36 ± 2# 38 ± 2#
Values are expressed as mean ± standard error of the mean. s indicates systole; d, diastole; LV, left ventricular; AW, anterior wall; PW, posterior wall; ID, internal diameter;
FS, fractional shortening. ∗P < 0.05 vs. age-matched sham. #P < 0.05 vs. AB-Co. $P < 0.05 vs. AB-Cin. †P < 0.05 vs. week 6.
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FIGURE 3 | Protective effect of pressure unloading and cinaciguat treatment against myocardial fibrosis. Representative microphotographs of the left ventricular
myocardium after Masson’s trichrome staining are presented. (A) After week 6, the pro-fibrotic genes (transforming growth factor-β [TGF-β]; matrix
metalloproteinase-2 [MMP-2], tissue inhibitor of matrix metallopeptidase-2 [TIMP-2], collagen type 1 α1 [Col1a1] and collagen type 3 α1 [Col3a1]) were activated in
the aortic banded (AB) group. However, at this time point Masson’s trichrome staining revealed physiologically low levels of interstitial fibrosis. (B) In contrast, after
week 12, the AB-Co group was associated with increased collagen accumulation. Both pressure unloading and cinaciguat therapy effectively inhibited the increment
in myocardial fibrosis. ∗P < 0.05 vs. age-matched sham. #P < 0.05 vs. AB-Co.
effect on myocardial hypertrophy. However, cinaciguat enhanced
the activity of the cardiac PKG enzyme, and selectively inhibited
pathological processes of myocardial fibrosis, nitro-oxidative
stress and apoptotic cell loss. Amelioration of PO-induced
pathological structural alterations prevented the deterioration
of LV systolic function (contractility and EF) and improved
myocardial stiffness.
Abolition of the pathological primary trigger of PO by
pressure unloading (anti-hypertensive medications, aortic valve
replacement) induces the regression of LVH, a phenomenon
called myocardial reverse remodeling (Treibel et al., 2018).
Correspondingly, a previous study has reported that in
a renovascular hypertensive rat model, where cinaciguat
was able to markedly lower blood pressure, pharmacological
activation of the sGC enzyme efficiently attenuated the
development of LVH (Kalk et al., 2006). Interestingly, besides
the secondary anti-remodeling ability of cinaciguat (due to its
anti-hypertensive effect), a recent in vitro experiment suggested
that cinaciguat could also exert direct anti-hypertrophic effects
on rat cardiomyocytes (Irvine et al., 2012). In accordance with
this finding, we have also found that preventive administration
of cinaciguat could suppress the manifestation of myocardial
hypertrophy independently of elevated PO (Nemeth et al.,
2016). However, whether long term activation of sGC by
cinaciguat could also reverse a pre-established LVH via its
direct cardioprotective effect has not been tested yet. To
address this issue, in the present study we intentionally chose a
surgical model of PO-induced LVH (abdominal AB rat model),
where the mechanical constriction of the aorta eliminated the
potential anti-hypertensive properties of the drug. Therefore,
this model allowed us to investigate separately the effect of
pressure unloading (which was achieved by removing the
aortic constriction) and sGC activation at persistently elevated
arterial blood pressure on pathological LVH. In this particular
experimental set up, we found that the direct anti-remodeling
effect of cinaciguat alone (without lowering blood pressure),
could only slightly influence a pre-established LVH. Accordingly,
only CD and the ratio of β/α-MHC showed significant decrement
from the conventional hypertrophy markers in the cinaciguat
treated AB group compared to the non-treated AB group
(Figure 2). In contrast, debanding of the abdominal aorta
markedly decreased arterial blood pressure and resulted in
substantial regression of HW/TL, LV mass, LV mass index,
LVAWs, LVAWd, and CD (Figure 2 and Table 1).
Pressure overload not only induces cardiomyocyte
hypertrophy but also facilitates the transformation of fibroblasts
into myofibroblasts leading to intensified expression of pro-
fibrotic genes and ultimately to increased collagen accumulation
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FIGURE 4 | Pressure unloading as well as cinaciguat administration reduces myocardial nitro-oxidative stress. Representative images of 3-nitrotyrosine (3-NT)
stained sections are shown. (A,B) In the aortic banded (AB) groups after week 6 and 12, increment in 3-NT content of the cardiomyocytes and increased mRNA
level of NAPDH oxidase family member 2 (NOX2) indicated increased oxidative stress in the myocardium. Furthermore, after week 6 the mRNA level of glutathione
peroxidase 4 (GPX4) was also significantly elevated. In contrast, both pressure unloading and cinaciguat evoked potent anti-oxidant effects and decreased 3-NT
content and NOX2 expression and increased mRNA level of GPX4. ∗P < 0.05 vs. age-matched sham. #P < 0.05 vs. AB-Co.
FIGURE 5 | Apoptotis is inhibited by pressure unloading and cinaciguat treatment. Representative images of Terminal deoxynucleotidyl transferase-mediated dUTP
nick end-labeling (TUNEL) stainings are shown. (A) At week 6, none of the apoptotic markers showed changes in the aortic banded (AB) group. (B) In contrast, after
week 12 in the AB-Co group the TUNEL positive nuclei increased, while expression of B cell lymphoma-2 (Bcl-2) decreased significantly compared to the Sham-Co
group. These alterations were successfully prevented either by cinaciguat treatment or pressure unloading. ∗P < 0.05 vs. age-matched sham. #P < 0.05 vs. AB-Co.
in the myocardium (Creemers and Pinto, 2011). Therefore,
reactive interstitial fibrosis is another hallmark of PO-induced
adverse remodeling, and it underlies the electrical disturbances
and cardiac dysfunction seen in LVH. In our experiment, obvious
signs of extracellular matrix remodeling on the gene expression
level could be detected at week 6, as observed by the increased
mRNA levels of Col1a1, Col3a1, TGF-β, TIMP-2, MMP-2 in the
aortic banded group (Figure 2). The activation of the pro-fibrotic
signaling resulted in excessive interstitial collagen accumulation
for week 12. In line with previous findings (Gao et al., 2005),
termination of PO in the debanded group effectively attenuated
the fibrotic alterations. Furthermore, long term treatment
with the sGC activator, cinaciguat, at sustained PO exerted as
potent anti-fibrotic effects as pressure unloading (Figure 2).
Our results are supported by previous data by Masuyama et al.,
2009. In their investigation another class of compounds, the
so called sGC stimulators, was utilized which, in contrast to
the sGC activators, stimulates the reduced hem-containing
cGC enzyme. Using the same animal model, they reported that
pharmacological elevation of myocardial cGMP content resulted
in robust inhibition of cardiac fibrosis (Masuyama et al., 2009).
Interestingly, this effect proved to be independent of blood
pressure reduction. Furthermore, similar to our results, they also
found that the anti-fibrotic action of sGC modulation could have
been already provoked by administration of non-suppressor
doses of the drug, while the anti-hypertrophic effects required
a reduction in blood pressure (Masuyama et al., 2006). These
and our findings might be explained by the observation, that
an equivalent amount of the sGC stimulator 41–2272 led to
a much higher enrichment of cGMP in fibroblasts compared
to myocytes (Masuyama et al., 2009). Therefore, due to their
unique sensitivity for cGMP elevation, (myo)fibroblasts might
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FIGURE 6 | Effect of pressure unloading and cinaciguat on hemodynamic parameters. Representative pressure–volume (P–V) loops are shown. (A) At week 6, in the
aortic banded group, increased mean arterial pressure (MAP) and arterial elastance (Ea) (MAP, Ea), increased contractility (slope of the end-systolic pressure–volume
relationship, ESPVR) maintained ejection fraction (EF) and impaired active relaxation (TauGlantz) and stiffness (slope of the end-diastolic pressure-volume relationship)
were detected. (B) At week 12 in the AB-Co group, increased arterial load and and diastolic dysfunction were also present. Furthermore, systolic performance was
impaired as well, as detected by the reduced ESPVR and EF values. Pressure unloading decreased MAP and Ea, restored diastolic dysfunction and prevented the
reduction in EF. In contrast, cinaciguat did not influence the increased afterload but increased ESPVR and maintained adequate EF values. Furhtermore, the
impairment in EDPVR was also inhibited by cinaciguat, although the prolonged active relaxation (TauGlantz) did differ from the AB-Co group. ∗P < 0.05 vs.
age-matched sham. #P < 0.05 vs. AB-Co. $P < 0.05 vs. AB-Cin.
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FIGURE 7 | Modulation of the cGMP signaling in the myocardium by pressure unloading and cinaciguat treatment. (A) Aortic banding (AB) induced increased
myocardial expression of atrial natriuretic peptide (ANP) at week 6, resulting in enhanced plasma/myocardial cyclic guanosin monophosphate (cGMP) levels.
Expression and activity of protein kinase G (PKG) remained unchanged at this time point. (B) At week 12, mRNA levels of ANP and plasma/myocardial cGMP levels
increased in the AB-Co group. In addition, in this group PKG expression tended to increase on the mRNA and on the protein level as well, however, no alterations
could be detected in its activity. Pressure unloading resulted in the deactivation of the cGMP pathway. In contrast, cinaciguat treatment led to increased PKG activity
(as detected by increased p-VASP/VASP ratio) despite the fact, that myocardial cGMP levels did not differ from that of the AB-Co group. ∗P < 0.05 vs. age-matched
sham. #P < 0.05 vs. AB-Co.
be one of the primary target cells of cGC activators/stimulators,
providing protection against the fibrotic remodeling in many
cardiovascular and non-cardiovascular pathologies.
Nitro-oxidative stress plays a major role in the
pathophysiology of LVH (Takimoto and Kass, 2007). PO induces
the generation of ROS via different mechanisms including
the activation of the NADPH oxidases, which contribution
particularly in the initiation phase is considered to be dominant
(Murdoch et al., 2006). Consistently, in pathological LVH animal
models, increased expression of NADPH oxidase subunits
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(including the catalytic NOX2 subunit) was reported (Li et al.,
2002). Furthermore, in mice with LV PO lacking the NOX2
gene due to genetic modifications, myocardial fibrosis and
contractile dysfunction was attenuated compared to their wild
type littermates (Grieve et al., 2006).
Beside the increased production, the enzymatic anti-oxidant
defense system (including e.g., catalase, glutathione peroxidase)
also often becomes inadequate during the development of
LVH. In addition, enhanced level of ROS also decreases
the bioavailability of NO by forming the cytotoxic, reactive
compound peroxynitrite (Szabo et al., 2007). The generated
reactive oxygen and -nitrogen species (RNS) subsequently lead
to the oxidation and tyrosine-nitration of numerous target
proteins, thereby regulating their activity. In our experiment,
PO already induced substantial impairment in the nitro-
oxidative status of the myocardium after week 6, which
became even more pronounced after week 12, as observed
in the increased 3-NT contents of the cardiomyocytes, and
also by the enhanced mRNA levels of NOX2 (Figure 4).
Interestingly, we found increased expression levels of the
anti-oxidant GPX4 in the AB groups which may suggest
an inadequate compensatory mechanism (Figure 4). Removal
the aortic constriction efficiently terminated the pathological
trigger of cardiomyocyte ROS production and restored the
elevated 3-NT content and NOX2 expression. In addition,
chronic activation of the sGC enzyme also led to significant
improvement in the nitro-oxidative status of the myocardium,
and the same alterations as seen in the debanded group
(decreased 3-NT and NOX2) could also be observed in
the cinaciguat treated AB group (Figure 4). Furthermore,
both interventions equally reinforced the cardiomyocytes’
defense capacity against oxidative injury by increasing GPX4
expression.
Progressive apoptotic cardiomyocyte loss is commonly
observed in LVH particularly during the development of
systolic dysfunction and chamber dilatation (Teiger et al., 1996;
Condorelli et al., 1999). PO-induced alterations in the expression
of the Bcl-2 family members, as well as increased peroxyinitrite
exposure are major determinants of this process (Condorelli
et al., 1999; Levrand et al., 2006). In our investigation, we
observed no signs of apoptosis after week 6 in the AB group.
However, the number of TUNEL positive nuclei were increased
in the non-treated AB group after week 12. We found, that
both pressure unloading and cinaciguat provided protection
against the programmed cell death, which could be explained
by normalized Bcl-2 expression and decreased 3-NT content
(Figure 5).
Pathological LVH is associated with typical functional
alterations. From a hemodynamic perspective, the early phase
of LVH can be considered as an adaptive reaction of the
heart, as it leads to an increment in cardiac contractility and
maintained systolic function. However, diastolic function is
often already disturbed during the “compensatory phase”
(Olah et al., 2016). In accordance, in the AB rats after week
6, systolic function proved to be preserved, as detected by
echocardiography (FS) and also by the invasive hemodynamic
measurement (EF) (Table 1 and Figure 6A). In addition,
P–V analysis revealed increased cardiac contractility (ESPVR)
and impaired diastolic function (TauG, EDPVR) in these
animals (Figure 6A). In PO small animal models, after a
certain period of time (depending on the severity of the
applied constriction) a deterioration of systolic function is also
commonly observed (Boluyt et al., 2005). In our experiment,
in the AB group at week 12, evident signs of functional
decompensation (reduction of maladaptive contractility
augmentation and impairment of EF and FS) were present. In
line with previous literature data (Chen et al., 2011; Ruppert
et al., 2016), regression of LVH by pressure unloading was
accompanied by the restoration of all the cardiac functional
abnormalities (Table 1 and Figure 6B). In contrast, cinaciguat
did not reversed pre-established myocardial hypertrophy,
but selectively inhibited interstitial fibrosis, oxidative stress
and apoptosis. Accordingly, on the functional level, we
also found that alterations which were the consequences of
cardiomyocyte hypertrophy (prolonged active relaxation time)
remained unaltered (Figure 6B), while those dysfunctions which
originated from the above mentioned deleterious cellular events
(reduced contractility, decreased EF and increased myocardial
stiffness) were effectively improved by cinaciguat treatment
(Figure 6B).
Furthermore, it is important to note here, that chronic
p.o. treatment with cinaciguat did not influence arterial blood
pressure and LV hemodynamics in healthy, control animals
(see the Supplementary Material). It is of particular interest,
since in the acute heart failure scenario, the, intravenous
administration of cinaciguat evoked severe hypotensive episodes.
However, the present results confirmed our previous findings
(Matyas et al., 2015; Nemeth et al., 2016) indicating that chronic
administration of cinaciguat is safe and it does not induce
hypotension.
Natriuretic peptides (ANP and brain type natriuretic
peptide) are intended to work as an in-built brake system
to attenuate the development of LVH. Under physiological
conditions their myocardial expression remains at a
low level. However, it considerably increases during
pathological states, when hemodynamic overload emerges.
In this case, ANP binds to its membrane receptor and
activates the particulate guanylate cyclase (pGC) enzyme
leading to cGMP elevation in the cells (Barry et al., 2008).
However, it was previously reported, that ANP-pGC derived
myocardial cGMP elevation did not lead to the same
extent of PKG activation compared to a pharmacological
activation of sGC or inhibition of PDE5 (Takimoto et al.,
2005; Nemeth et al., 2016). This phenomenon might be
explained by the fact that both pGC, sGC and PDE5,
as well as PKG and its target proteins are sub-localized
in distinct compartments within the cell. Therefore, one
can speculate that ANP-pGC derived cGMP elevation
represents an inadequate compensatory mechanism of
the diseased heart, which can not be efficiently translated
into the activation of the protective PKG signaling.
The stress-activated nature of the ANP-pGC-cGMP axis
was well reflected by our investigation. Accordingly,
we found a robust increase in ANP expression in the
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non-treated AB groups, leading to elevated plasma and
myocardial cGMP levels (Figure 7). In contrast, eliminating the
pathological stimulus of PO in the debanded group led to the
deactivation of the pathway (Figure 7B). Chronic activation of
the sGC enzyme by cinaciguat decreased ANP expression and
plasma cGMP, however, myocardial cGMP remained elevated,
indicating that a higher amount of total cGMP originated from
sGC activation. Consistently, enhanced activation of PKG (as
detected by p-VASP/VASP ratio) could only be observed in the
cinaciguat treated group (Figure 7B). Therefore, our experiment
provides further evidence, that although the ANP-pGC-cGMP
pathway is activated under pathological conditions (as observed
in elevated ANP expression, enhanced plasma/myocardial
cGMP levels and tendentially increased PKG expressions),
pharmacological activation of the sGC enzyme might lead to
cGMP production in other compartments resulting in enhanced
PKG activity.
In recent years, many molecular mechanisms have
been proposed by which the activated PKG attenuates
pathological structural and functional alterations. Inter alia,
these involve modulation of intracellular signaling pathways
[e.g., the calcineurin-NFAT signaling pathway (Fiedler et al.,
2002)], direct phosphorylation of titin residues (Kruger
et al., 2009) and enhancement of proteasome-mediated
degradation of misfolded proteins (Ranek et al., 2013).
The multiplex protective effect of PKG activation might
be attributed to the fact, that the NO-cGMP-PKG pathway
represents a complex endogenous defense system in the
myocardium.
CONCLUSION
Our results provide evidence, that the sGC activation by
cinaciguat and pressure unloading exposed reverse-remodeling
effects through different mechanisms. Pressure unloading
terminated the primary pathological stimulus of hypertrophic
remodeling, thereby leading to the regression of LVH associated
alterations on the molecular, cellular and functional level. In
contrast, activation of the sGC enzyme at sustained PO only
slightly influenced the pre-established LVH. However, chronic
cinaciguat therapy efficiently increased the activity of the PKG
enzyme in the myocardium and provided potent protection
against interstitial fibrosis, oxidative stress and apoptosis.
Amelioration of PO-induced pathological structural alterations
prevented the deterioration of LV systolic function (contractility
and EF) and improved myocardial stiffness.
Limitations
The interpretation of results from the current study is limited to
young male rats. The possible influence of age and gender should
be assessed in future studies.
Furthermore, the present study was specifically designed
to investigate the direct, blood pressure independent
cardioprotective effect of cinaciguat on pre-established LVH.
Therefore, in this particular experimental set up, cinaciguat could
exert only one way of its mechanisms (the direct anti-remodeling
effect) while its potent vasodilatative and anti-hypertensive
effects did not prevail. Hence, it is required to further study the
benefits of cinaciguat in animal models with different etiologies
of hypertensive heart disease, where the combination of the two
therapeutic properties can both manifest.
DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this manuscript will
be made available by the authors, without undue reservation, to
any qualified researcher.
AUTHOR CONTRIBUTIONS
MR, SK-I, NG, SP, BM, MK, TR, and GS were involved in study
design and conception. MR, SK-I, SL, BN, AO, PB, GV, EH, and
TR were involved in data acquisition. MR, SK-I, PB, and TR
conducted data analysis. MR and TR wrote the first draft of the
manuscript. SK-I, PB, BM, TR, and GS reviewed the manuscript
for important intellectual content. All authors read and approved
the final manuscript.
FUNDING
The study was supported by the New National Excellence
Program of the Ministry of Human Capacities (ÚNKP-18-3-
I-SE-9 to MR), (EFOP-3.6.3-VEKOP-16-2017-00009 to MR),
the Higher Education Institutional Excellence Program of the
Ministry of Human Capacities in Hungary, within the framework
of the Therapeutic Development thematic program of the
Semmelweis University, the National Research, Development and
Innovation Office of Hungary (NKFIA, NVKP-16-1-2016-0017),
the Land Baden-Württemberg, Germany, by the Medical Faculty
of the University of Heidelberg Germany (to SK-I), and the
János Bolyai Research Scholarship of the Hungarian Academy of
Sciences (to TR).
ACKNOWLEDGMENTS
The excellent technical assistance of Patricia Kraft, Tobias
Mayer, Karin Sonnenberg, Lutz Hoffmann is acknowledged.
Furthermore, the authors gratefully acknowledge for Peter
Sandner and Johannes-Peter Stasch from Bayer HealthCare
(Wuppertal, Germany) for providing cinaciguat. The authors
state that the abstract has been previously published as a
conference abstract (at the World Congress on Acute Heart
Failure, 2018, Vienna).
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fphys.
2018.01869/full#supplementary-material
Frontiers in Physiology | www.frontiersin.org 14 January 2019 | Volume 9 | Article 1869
fphys-09-01869 December 29, 2018 Time: 18:47 # 15
Ruppert et al. Cinaciguat vs. Pressure Unloading in LVH
FIGURE S1 | Effect of cinaciguat treatment on pathological myocardial left
ventricular hypertrophy and fibrosis in control animals.
FIGURE S2 | Effect of cinaciguat treatment on oxidative stress and apoptosis.
FIGURE S3 | Effect of cinaciguat treatment on hemodynamic parameters in
control animals.
FIGURE S4 | Effect of cinaciguat treatment on cGMP signaling.
IMAGE S1 | Original western blot for p-VASP/VASP at week 6.
IMAGE S2 | Original western blot for p-VASP/VASP at week 12.
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TABLE S5 | Effect of cinaciguat on basic parameters in sham rats.
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